Your institution may have access to this item. Find your institution then sign in to continue.
Title
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
Authors
Sinnathamby, G.; Zerfass, J.; Hafner, J.; Block, P.; Nickens, Z.; Hobeika, A.; Secord, A. A.; Lyerly, H. K.; Morse, M. A.; Philip, R.